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Abstract
New arylbismuth(lll) oxinates, PhBi(MeOx)2, (p-MeC6H4)Bi(Ox)2, (p-MeC6H4)Bi(MeOx)2,
(p-ClC6H4)Bi(Ox)2, and (p-CIC6H4)Bi(MeOx)2 (Ox-=quinolin-8-olate and MeOx-= 2-
methylquinolin-8-olate) have been prepared by reaction of the appropriate diarylbismuth chlorides
with Na(Ox) or Na(MeOx) in the presence of 15-crown-5. An X-ray crystallographic study has shown
PhBi(MeOx)2 to be a five coordinate monomer with distorted square pyramidal stereochemistry.
Chelating MeOx ligands have a cisoid arrangement in the square plane and the phenyl group is
apical. The lattice is stabilised by significant-
interactions between centrosymmetric molecules.
A range of these complexes has been shown to have high in vitro biological activity
(comparable with or better than cisplatin) against L1210 leukaemia, the corresponding cisplatin
resistant line, and a human ovarian cell line, SKOV-3. However, initial in vivo testing against a solid
mouse plasmacytoma (PC6) and P388 leukaemia has not revealed significant activity.
Introduction
It has been shown recently that metathetical reactions of Ph2BiX and PhBiX2 (X CI, Br, or I)
with sodium quinolin-8-olate (NaOx) are complicated by rearrangement reactions and by incomplete
elimination of sodium halides [1]. Typically bimetallics of composition PhBi(Ox)2(NaX)n were
isolated together with varying amounts of Bi(Ox)3. However, halide-free PhBi(Ox)2 was isolated
from the reaction of Ph2BiCI with Na(Ox) in the presence of 15-crown-5 and from reaction of PhBil2
with Bu4N(Ox). The low solubility of PhBi(Ox)2 suggested an associated structure but no clear
structural conclusions could be drawn from spectroscopic data.
We now report the synthesis of a range of pure organobismuth quinolin-8-olate and
2-methylquinolin-8-olate complexes, RBi(Ox)2 and RBi(MeOx)2, the X-ray crystal structure of
PhBi(MeOx)2 and a preliminary survey of the anti-cancer activity of these quinolin-8-olate
complexes together with some related reference compounds.
There has been sporadic interest in antitumour properties of bismuth compounds [2-7] the
most successful of which have been methylbismuth(lll) thiolates. In addition, it has been shown that
8-quinolinol has antitumour activity [8,9]. Bismuth compounds are much more widely used in the
treatment of gastrointestinal disorders [7] and of peptic ulcers [10]. The low toxicity of most bismuth
compounds, especially relative to that of many other heavy metal compounds, makes them
attractive candidates for drug usage [7]. It has been observed, however, that regular ingestion of
high doses of bismuth salts (5 15 g/day by many French citizens) led to ca 300 cases of
bismuth(Ill) intoxication with some deaths in 1976 [11].
Experimental
Instruments and Procedures
Details have been described previously [1].
Reagents
Sodium salts of quinolin-8-ol and 2-methylquinolin-8-ol were prepared as described
previously [1]. The following diarylbismuth chlorides were prepared by reaction of stoichiometric
amounts of BiCl3 and Ar3Bi [12]: Ph2BiCl, m.p. 185-186 (dec.)lit. [13] 184-185C;
295Vol. 5, No. 5, 1998 Preparation and Anti-Tumour Activity ofSome Arylbismuth(III) Oxine Complexes
(4-CH3C6H4)2BiCI, m.p. 182C (dec.)lit. [14] 181C; (4-CIC6H4)2BiCI, 1H nmr (300 MHz) 6, 7.57, d,
J8.3 Hz, 4H, H3,5; 8.36, d, J8.2 Hz, 4H, H2,6. The compounds Bi(Qx)3, Bi(Ox)21, PhBil2, Ph2Bil,
PhBi(Ox)2.EtOH, [M{PhBi(Ox)3}] (M Na or K) were available from an earlier study [1], and Ph3Bi
was from Warman International.
Reactions of diarylbismuth chlorides with oxinate salts,
Ph2BiCI + Na(MeOx)
A solution of Na(MeOx) (0.98 g, 5.4 mmol) in ethanol (25 ml) with 15-crown-5 ether (2.38 g,
2.1 ml, 10.8 mmol) was added to a suspension of Ph2BiCl (2.15 g, 5.4 mmol) in ethanol (10 ml).
The yellow reaction mixture was stirred for 2 h then filtered. The yellow solid was collected,
washed with ethanol (3 x 5 ml), light petroleum (3 x 10 ml) and dried to yield bis(2-
methylquinolin-8-olato)phenylbismuth(lll) (1.45 g, 89%)t (Found: C, 51.6; H, 3.4; N, 4.6. Calc.
for C26H21BiN202: C, 51.8; H, 3.5; N, 4.7%). Vmax 1599w, 1585m, 1557s, 1502s, 1427s,
1327s, 1294m, 1270s, 1234w, 1212w, 1186w, 1169w, 1102vs, 1055m, 1032w, 998m, 966m,
916w, 871m, 844s, 826s, 790m, 751s, 737vs, 724s, 691m, 605m cm1. 1H nmr (300 MHz) 5
2.83, s, 6H, CH3; 6.91, d, J7.7 Hz, 2H, H7; 7.05, m, 3H, H4’, 5; 7.44, m, 6H, H3’, 5’, 3, 6; 8.16,
d, J7.3 Hz, 2H, H2’, 6’; 8.31, d, J8.4 Hz, 2H, H4. 13C nmr 24.14, CH3; 112.95, C7; 117.31,
C5; 122.52, C3; 127.38, C4’; 128.48, C6; 129.06, C4a; 131.57, C3’, 5’; 134.77, C2’, 6’;
138.22, C4; 141.71, C8a; 154.36, C2; 162.10, C8; C1’ not observed.: Mass spectrum m/z602
(<1%, M), 525 (6, Bi(MeOx)2+), 444 (22, PhBi(MeOx)+), 367 (18, Bi(MeOx)+), 286 (18, PhBi+), 209
(63, Bi+), 159 (100, MeOxH+), 154 (44, Ph2+), 131 (63), 103 (18), 77 (30, Ph+), 51 (23, C4H3+).
UV/Vis (2.07 x 10-4 M in (CH3)2SO) 320 (sh)( 4406), 337 (sh)(s 5097), 371 nm (e6908) (solid
state) 402 nm. The solvent was removed from the filtrate to yield a yellow solid which was extracted
with water (6 x 10 ml) and ether (6 x 10 ml). NaCI and 15-crown-5 ether (2.92 g, ca. 100%)
were isolated from the water extraction. Removal of the solvent from the ether extraction yielded
Ph3Bi (1.22 g, ca. 100%)identified by 1H n.m.r, spectroscopy.
(4-CH3C6H4)2BiCI + Na(Ox)
A solution of Na(Ox) (0.89 g, 5.3 mmol) with 15-crown-5 ether (2.34 g, 2.1 ml,
10.6 mmol) in ethanol (25 ml) was added to a suspension of (4-MeC6H4)2BiCI (2.27 g, 5.3 mmol)
in ethanol (20 ml)o The reaction mixture became a clear yellow colour before a yellow precipitate
appeared. After stirring for 2 h, the reaction mixture was filtered and the resulting yellow solid was
washed with ethanol (3 x 5 ml) and light petroleum (3 x 10 ml)o This solid was further stirred for
h in ether (50 ml) to fully remove the (4-MeC6H4)3Bi which was also formed, then refiltered and
rewashed with ether (50 ml), ethanol (2 x 20 ml), light petroleum (2 x 20 ml) and dried to yield
(4-methylphenyl)bis(quinolin-8-olato)bismuth(lll) (1.31 g, 78%). The 1H nmr spectrum of the
product taken a week later showed that the intensity of the resonances assigned to ethanol had
decreased to give a mole ratio of 10" (Found: C, 49.9; H, 3.3; N, 4.7. C25H19BiN202 requires C,
51.0; H, 3.3; N, 4.8. C25H19BiN202.(C2H60)0.1 requires C, 51.0; H, 3.3; N, 4.7%).
Vmax 1917w, 1624w, 1602m, 1585s, 1494s, 1423m, 1313s, 1269s, 1233s, 1186w, 1171m,
1135w, 1101vs, 1071w, 1061 m, 1032m, 1016m, 982w, 962w, 898m, 823s, 802s, 789s, 751s,
725vs, 644m, 610w cm-1. 1H nmr (300 MHz) ;51.07, t, J 7.0 Hz, 3H, CH3; 1.98, s, 3H, CH3-Ar;
3.46, m, 2H, CH2; 4.39, t, J5.1 Hz, 1H, OH; 6.87, m, 4H, H5, 7; 7.17, d, J7.6 Hz, 2H, H3’, 5’;
7.41, t, J7.9 Hz, 2H, H6; 7.60, dd, J8.2, 4.5 Hz, 2H, H3; 8.33, d, J8.3 Hz, 4H, H2’, 6’, 4;
9.28, d, J3.7 Hz, 2H, H2. 13C n.m.r. 20.86, CH3-Ar; 110.29, C7; 116.07, C5; 121.23, C3;
129.70, C6; 131.27, C4a; 131.68, C3’, 5’; 135.08, C2’, 6’; 135.77, C4’; 137.62, C4; 142.36,
C8a; 145.55, C2; 164.32, C8; 212.11, C1’. Mass spectrum m/z (no M), 444 (1%, ArBi(Ox)+), 391
(2, Ar2Bi+), 360 (1), 300 (96, ArBi+), 209 (100, Bi+), 182 (22, Ar2+), 165 (10), 144 (10, Ox+), 91 (10,
Ar+), 65 (7). UV/Vis (1.25 x 10-4 in Me2SO) 323 (sh) ( 3454), 339 ( 4126), 391 nm) ( 5925).
(solid state) 400 nm. The solvent was removed from the filtrate to yield a yellow solid. This was
extracted with water (6 x 10 ml) and ether (6 x 10 ml)o NaCI was isolated from the aqueous
Yields are calculated on the basis of reaction
Prime numbers refer to atoms in the aryl group attached directly to bismuth
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extract (0.28 g, 90% by AgNO3 titration). The ether washings were combined and evaporated to
yield (4-CH3C6H4)3Bi (1.22 g, 95%).
(4-MeC6H4)2BiCl + Na(MeOx)
A solution of Na(MeOx) (0.89 g, 4.9 mmol) with 15-crown-5 ether (2.16 g, 2.0 ml,
9.8 mmol) in ethanol (20 ml) was added to a suspension of (4-MeC6H4)2BiCI (2.10 g, 4.9 mmol)
in ethanol (20 ml). The reaction mixture became a clear yellow colour before a yellow precipitate
appeared. After stirring for 2 h, the reaction mixture was filtered and the resulting yellow solid was
washed with ethanol (3 x 5 ml) and light petroleum (3 x 10 ml). The sample was further stirred
in ether (50 ml) for h to fully remove (4-MeC6H4)3Bi. The suspension was filtered and the solid
coliected, rewashed with ether (2x 20ml), ethanol (2x 10ml) and light petroleum
(2 x 20 ml) to yield (4-methylphenyl)bis(2-methylquinolin-8-olato)bismuth(lll) (1.30 g, 86%)
(Found: C, 52.6; H, 3.7; N, 4.5. C27H23BiN202 requires C, 52.6; H, 3.8; N, 4.5%). Vmax 1915w,
1738w, 1602w, 1586m, 1555s, 1503s, 1488w, 1429s, 1330s, 1297m, 1275s, 1210w, 1190m,
1170w, 1140w, 1103s, 1053m, 1014w, 974w, 961w, 919w, 866m, 832s, 796s, 758s, 749s,
738vs, 696w, 668w, 607m cm-1. 1H nmr (300 MHz) 5 2.01, s, 3H, CH3-Ar; 2.83, s, 6H, CH3; 6.90,
d, J7.7Hz, 2H, H7; 7.01, d, J7.9Hz, 2H, H5; 7.24, d, J7.6Hz, 2H, H6; 7.40, t, J7.8Hz, 2H,
H3’, 5’; 7.49, d, J8.4 Hz, 2H, H3; 8.02, d, J7.6 Hz, 2H, H2’, 6’, 8.34, d, J8.4 Hz, 2H, H4. 13C
nmr 5 20.88, CH3-Ar; 24.41, CH3; 112.86, C7; 117.25, C5; 122.48, C3; 128.45, C6; 129.04,
C4a; 132.17, C3’, 5’; 134.67, C4’; 136.61, C2’, 6’; 138.18, C4; 154.28, C2; 162.18, C8; C8a
and C1’ were not observed. Mass spectrum m/z (no M), 525 (1%, Bi(MeOx)2+), 458 (2,
ArBi(MeOx)+), 391 (1, Ar2Bi+), 367 (2, Bi(MeOx)+), 336 (4, Bil+), 300 (20, ArBi+), 209 (30, Bi+), 182
(22, Ar2+), 159 (100, MeOxH+), 131 (63), 91 (20, Ar+), 77 (10, Ph+), 65 (18). U.v.-vis.
(8.04 x 10-5 M in Me2SO) 319 (sh) (e 4214), 337 (sh) (e 4649), 371 nm (e 6054). (Solid state)
400 nm. The solvent was removed from the filtrate to yield a pale yellow solid. This was extracted
with water (6 x 10 ml) and ether (6 x 10 ml). NaCI (0.29 g, 98% by AgNO3 titration) was
isolated from the aqueous washings. The solvent was removed from the ether extract to yield
(4-MeC6H4)3Bi (1.13 g, 96%) identified by 1H nmr spectroscopy.
(4-ClC6H4)2BiCI + Na(Ox)
A solution of Na(Ox) (0.50 g, 3.0 mmol)in ethanol (20 ml) with 15-crown-5 ether (1.32 g,
1.2 ml, 6.0 mmol) was added to a solution of (4-CIC6H4)2BiCI (1.72 g, 3.7 mmol) in ethanol
(40 ml). A yellow precipitate gradually appeared and the reaction mixture was stirred for 2 h. The
yellow solid was collected by filtration, washed with ethanol (3 x 5 ml), light petroleum
(3 x 10ml) and dried to yield an ethanol solvate of (4-chlorophenyl)bis(quinolin-8-
olato)bismuth(lll) (0.91 g, 93%) (Found" C, 44.1; H, 2.7; CI, 5.4; N, 3.9. C24H16BiCIN202
requires C, 47.4; H, 2.7; CI, 5.8; N, 4.6. C24H16BiClN202.C2H60 requires C, 47.7; H, 3.4; CI,
5.4; N, 4.3%). Vmax 1914w, 1602m, 1566vs, 1494vs, 1420m, 1312vs, 1269vs, 1233s, 1171m,
1100vs, 1086s, 1050m, 1033w, 1008s, 960w, 888w, 884w, 823s, 804m, 788m, 749m, 725s,
644w cm-1. 1H nmr (300 MHz) 1.06, t, J 7.0 Hz, 3H, CH3; 3.47, m, 2H, CH2; 4.38, t, J 5.0 Hz,
1H, OH; 6.86, d, J7.7 Hz, 2H, H7; 6.90, d, J8.0 Hz, 2H, H5; 7.39, m,4H, H3’, 5’, 6; 7.60, dd,
J8.2, 4.5 Hz, 2H, H3; 8.33, d, J8.0 Hz, 2H, H4; 8.47, d, J8.0 Hz, 2H, H2’, 6’; 9.30, d,
J 3.9 Hz, 2H, H2. 13C nmr i5 110.52, C7; 116.13, C5; 121.27, C3; 129.71, C6; 130.75, C3’, 5’;
131.24, C4a, 131.35, C4’; 137.04, C2’, 6’; 137.73, C4; 142.28, C8a; 145.71, C2; 164.10, C8;
C1; not observed. Mass spectrum m/z (no M), 431 (2%, Ar2Bi+), 320 (60, ArBi+), 222 (12, Ar2+),
209 (100, Bi+), 152 (7), 111 (4, Ar+), 76 (8); UV/Vis (5.47 x 10-5 M in (CH3)2SO) 325 (sh)
(e 4117), 339 (e 4556), 389 nm (e 6184). (Solid state) 390 nm.
(4-CIC6H4)2BiCl + Na(MeOx)
A solution of Na(MeOx) (0.36 g, 2.0 mmol) with 15-crown-5 ether (0.86 g, 0.8 ml,
3.9 mmol) in ethanol (25 ml) was added to a solution of (4-CIC6H4)2BiCI (0.92 g, 2.0 mmol) in
ethanol (20 ml). A pale yellow precipitate gradually appeared and the reaction mixture was stirred
for 2 h. The precipitate was collected by filtration, washed with ethanol (3 x 5 ml), light
petroleum (3 x 10 ml) and dried to yield (4-chlorophenyl)bis(2-methylquinolin-8-olato)bismuth(lll)
(0.57 g, 91%) (Found: C, 49.0; H, 3.2; CI, 5.7; N, 4.3. C26H20BiCIN202 requires C, 49.0; H, 3.2;
CI, 5.6; N, 4.4%). Vmax 1587m, 1558s, 1502s, 1429s, 1328s, 1298m, 1274vs, 1238w, 1170w,
1104s, 1091s, 1053m, 1005m, 972w, 868w, 833s, 808m, 795w, 752s, 738s, 717m, 698w,
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608m cm -1. 1H nmr (300MHz) 5 2.83, s, 6H, CH3; 6.91, d, J7.7Hz, 2H, H7; 7.03, d,
J7.9Hz, 2H, H5; 7.45, m, 6H, H3’, 5’, 3, 6; 8.17, d, J7.9Hz, 2H, H2’, 6’; 8.32, d, J8.4Hz,
2H, H4. 13C nmr 5 24.46, CH3; 113.15, C7; 117.40, C5; 122.54, C3; 128.49, C6; 129.07, C4a;
129.96, C4’; 131.33, C3’, 5’; 136.70, C2’, 6’; 138.29, C4; 141.71, C8a; 154.53, C2; 161.93, C8;
213.68, C1’o Mass spectrum m/z (no M), 525 (1%, Bi(MeOx)2+), 478 (2), 431 (<1, Ar2Bi+), 367 (2,
Bi(MeOx)+, 336 (1, Bil+), 320 (11, ArBi+), 222 (13, Ar2+), 209 (35, Bi+), 159 (100, MeOxH+), 131
(64), 112 (7, ArH+), 103 (12), 77 (21, Ph+), 51 (18). UV/Vis (9.95 x 10-5 M in Me2SO) 319 (sh)
( 6169), 336 (sh) ( 6893), 370 nm ( 8942). (Solid state) 388 nm. The solvent was removed
from the filtrate to yield a pale yellow solid. This was extracted with water (6 x 10 ml) and ether
(6 x 10 ml). The aqueous extract yielded NaCI (0.11 g, 96% by AgNO3 titration) and the ether
extract yielded (4-CIC6H4)3Bi (0.50 g, 94%) identified by 1H nmr spectroscopy.
In Vitro Growth Inhibition and In Vivo Antitumour Testing
The methods for testing the compounds for growth inhibition against L1210 or the cisplatin
resistant derivative L1210/DDP mouse leukaemia cells in vitro and P388 mouse leukaemia in vivo
have been described previously [15]. Briefly, for the cell culture testing, cells were exposed to the
drug at several concentrations for 48 h, after which they were counted using a Coulter counter
(Model ZM) and compared to control cells grown in the presence of only the vehicle. The IC50, or
concentration causing 50% inhibition of cell growth, was determined from the curve of percentage
growth versus drug concentration. The SKOV-3 human ovarian carcinoma cell line was maintained
in o-minimum essential medium plus 15% foetal calf serum. For these growth inhibition studies,
5x103 exponentially growing cells in 100 #1 medium were allowed to adhere in 96-well culture plates
for 12 to 16 h at 37C in a humidified incubator gassed with 10% CO2/90% air. Drugs were
dissolved in Me2SO and diluted in medium to 10 concentrations over a 4-log range, and 100 #1 of
each drug solution was added to 5 wells. Cells were incubated for a further 72 h, after which viable
cells were measured using the sulforhodamine B (SRB) assay [16] that measures cellular protein
content. Briefly, cells were fixed with trichloroacetic acid and stained with SRB. Unbound dye was
removed by washing with acetic acid, protein-bound dye was solubilised with Tris base, and the
optical density was read at 550 nm using an automatic plate reader. The percentage cell growth
inhibition was calculated as described above. All in vitro tests were done in duplicate, with repeats if
greater than a 20% difference, and the results are reported as the mean.
All animal protocols were approved by the Institutional Animal Experimentation and Ethics
Committee. For the animal studies with mouse leukaemia, DBA/2 mice received 106 P388 cells
intraperitoneally (i.p.), and drugs were injected i.p. on days 1,5, and 9. Although increased lifespan
measured in days was the endpoint, animals were sacrificed prior to death, when movement was
restricted by ascites. Controls received vehicle only, and %T/C was calculated as the ratio of
survival time of treated animals over control animals, where compounds with %T/C greater that
125% were considered to have some activity.
For the in vivo antitumour activity against PC-6 plasmacytoma, female Balb/c mice (10-15 weeks old)
were maintained in controlled atmospheric conditions and fed standard mouse chow and water ad
lib.. The compounds were suspended by sonication in peanut oil. The murine PC6 plasmacytoma
(obtained from L. Kelland, Institute of Cancer Research, Sutton, U K) was inoculated as mm cubes
subcutaneously on the flanks of the mice, and approximately 20 days later, mice with tumours were
randomised into groups of 5 to 10 animals, which received either nothing (no-drug control), or an
intraperitoneal injection of peanut oil at 10 ml/kg (vehicle control), cisplatin in saline at 6 mg/kg
(positive control), or the test compounds at the maximum tolerated dose of 30 mg/kg. Eight to ten
days later, mice were sacrificed and the tumours were dissected and weighed. The results were
expressed as %T/C mean tumour weight of the treated animals over mean tumour weight of the
vehicle control group, where values less than 75% are considered to be worth further investigation.
Crystallography
Intensity data for a yellow crystal (0.21 x 0.21 x 0.21 mm) were measured at room temperature
on a Rigaku AFC6R diffractometer fitted with MoKo radiation (graphite monochromator, X
0.71073 A) using the e):2e scan technique so that 0max was 28.0. NO decomposition of the crystal
occurred during the data collection and the data set was corrected for Lorentz and polarization
effects [17], and for absorption employing an empirical procedure [18]. A total of 5905 data (5601
unique) were collected and of these, 3349 that satisfied the/_> 3.0(/) criterion were used in the
subsequent analysis.
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Crystal data: C26H21BiN202, M 602.4, monoclinic, space group P2/c, a 9.912(3) ,/k, b
15.004(2) ,&,, c 15.621 (2) ,&,, I 106.92(1), V= 2222.6(7) A3, Z= 4, Dcalc 1.800 g cm"3, F(000)
1160, 79.39 cm1
The structure was solved by direct-methods [19] and refined by a fu!.l-matrix least-squares
procedure based on F [17]. The non-hydrogen atoms were refined with anisotropic displacement
parameters and hydrogen atoms were included in the model in their calculated positions (C-H 0.97
A). The refinement was continued until convergence with sigma weights when R 0.032 and Rw
0.031. The maximum residual in the final difference map was 0.60 e ,&,-3. Fractional atomic
coordinates are listed in Table and the numbering scheme employed is shown in Fig. which was
drawn with ORTEP [20] at 50 % probability ellipsoids. Data manipulation was performed with the
teXsan program [17] installed on an Iris Indigo work station. Other crystallographic details,
comprising fractional atomic coordinates for all atoms, thermal parameters, all bond distances and
angles have been deposited at the Cambridge Crystallographic Data Centre; deposition no.
103306.
TABLE 1. Fractional atomic coordinates and Beq (A2)a values for [PhBi(MeOx)2]
Atom x y z Beq
Bi 0.55978(3) 0.33877(2) 0.98078(2) 2.718(5)
O(1) 0.7362(5) 0.2839(3) 0.9397(3) 3.7(1)
0(2) 0.5333(5) 0.4009(3) 0.8489(3) 3.7(1)
N(1) 0.7033(6) 0.2308(4) 1.1005(3) 2.9(1)
N(2) 0.3287(6) 0.4403(3) 0.9307(4) 3.1 (1)
C(1) 0.4170(7) 0.2255(5) 0.9194(5) 3.2(2)
C(2) 0.4267(9) 0.1418(5) 0.9585(6) 4.6(2)
C(3) 0.334(1 0.0746(5) 0.9201 (7) 5.8(3)
C(4) 0.232(1) 0.0884(6) 0.8418(7) 6.2(3)
C(5) 0.219(1) 0.1706(7) 0.8007(7) 7.4(3)
C(6) 0.314(1 0.2383(5) 0.8403(6) 5.3(2)
C(7) 0.8414(7) 0.2412(4) 0.9971(5) 3.1(2)
C(8) 0.9660(8) 0.2207(5) 0.9799(5) 4.2(2)
C(9) 1.0762(9) 0.1749(6) 1.0412(6) 5.4(2)
C(10) 1.0626(9) 0.1473(6) 1.1206(6) 5.3(2)
C(11) 0.9382(8) 0.1654(5) 1.1447(5) 3.9(2)
C(12) 0.8264(7) 0.2106(4) 1.0817(4) 3.0(2)
C(13) 0.6863(8) 0.2094(5) 1.1783(5) 3.6(2)
C(14) 0.5495(9) 0.2365(5) 1.1948(5) 4.7(2)
C(15) 0.7923(10) 0.1636(5) 1.2442(5) 4.6(2)
C(16) 0.9149(10) 0.1434(5) 1.2266(5) 4.7(2)
C(17) 0.4306(8) 0.4572(5) 0.8108(5) 3.6(2)
C(18) 0.4243(9) 0.4971 (5) 0.7293(5) 4.7(2)
C(19) 0.317(1) 0.5573(6) 0.6886(6) 5.7(2)
C(20) 0.2134(10) 0.5802(5) 0.7252(6) 5.4(2)
C(21) 0.2165(9) 0.5428(5) 0.8090(6) 4.2(2)
C(22) 0.3230(8) 0.4799(5) 0.8501 (5) 3.4(2)
C(23) 0.2381 (8) 0.4625(5) 0.9735(5) 3.8(2)
C(24) 0.2489(9) 0.4187(6) 1.0612(6) 5.2(2)
C(25) 0.1337(8) 0.5268(6) 0.9380(6) 4.5(2)
C(26) 0.1204(8) 0.5652(5) 0.8586(7) 5.1 (2)
a where Beq 8=2/3(U1 l(aa*)2 + U22(bb*)2 + U33(cc*)2 + 2U12aa*bb*cosy + 2U13aa*cc*cos13 +
2 U23bb*cc*coso)
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Results and Discussion
Preparation and characterisation of arylbismuth oxinates
A range of new arylbismuth(lll) oxinates, ArBi(Ox)2 (Ar p-MeC6H4 or p-CI6H4) and
ArBi(MeOx)2 (Ar Ph, p-Me6H4, or p-CIC6H4) have been prepared by reaction of diarylbismuth(lll)
chlorides with Na(Ox) or Na(MeOx)in ethanol in the presence of 15-crown-5.
2Ar2BiCI + 2Na(Ox or MeOx) --, ArBi(Ox or MeOx)2 + Ar3Bi + 2NaCI
The crown ether prevented retention of sodium chloride-by the arylbismuth oxinate [1]. In
representative cases, the amount of sodium chloride produced was shown to be ca. 90% as was
the yield of Ar3Bi. Reaction (1) rather than reaction of ArBiCI2 with Na(Ox or MeOx) was chosen to
avoid formation of Bi(Ox)3 or Bi(MeOx)3 [1], which cannot be separated from ArBi(Ox or MeOx)2
owing to their mutual low solubilities. The Ar3Bi compounds can be recycled by reaction with BiCl3
to give the reactants, Ar2BiCI. Most complexes were analytically pure except RBi(Ox)2
(R p-MeC6H4 or p-CIC6H4) where use of the crown ether makes it unlikely that the low carbon
analyses were due to sodium halide retention. Satisfactory 1H and 13C NMR spectra and UV/Vis
spectra (showing chelation of Ox and MeOx) [21,22] were obtained for all complexes including
RBi(Ox)2 (R p-MeC6H4 or p-CIC6H4). A COSY 1H NMR spectrum of PhBi(MeOx)2 showed that
H2,6 of the phenyl group was at lower frequency than H4 of MeOx by contrast with the reported
spectrum [1] of PhBi(Ox)2.
Molecular structure of PhBi(MeOx)2
The molecular structure of PhBi(MeOx)2 is illustrated in Figure and selected interatomic
parameters are listed in Table 2. This is the first structurally characterised bismuth(Ill) oxine complex.













02 O1 C8 C10
C9
Figure 1. The molecular structure of PhBi(MeOx)2
The bismuth atom is five coordinate, with distorted square pyramidal stereochemistry. The
square plane is defined by a N202 donor set derived from two chelating MeOx anions, and the
bismuth atom lies 0.0565(2) A above the least-squares plane through the N202 atoms (mean
deviation" 0.014 A). The square plane is significantly distorted towards a trapezoidal geometry
owing to the presence of disparate BiO and BiN distances. This disparity is manifested in the
wide N--BimN angle of 145.0(2) and may arise in order to minimise intramolecular repulsions
between the methyl groups. The phenyl group is almost symmetrically inclined with respect to the
BiN202 plane, forming a dihedral angle of 95.6 with it.
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+b
Figure 2. Unit cell contents for PhBi(MeOx)2
TABLE 2. Selected interatomic parameters (,&,, deg.) for PhBi(MeOx)2
Bi-O(1) 2.191 (4) Bi-O(2) 2.207(4)
Bi-N(1) 2.569(5) Bi-N(2) 2.671 (5)
Bi--C(1) 2.241(7) O(1)--C(7) 1.325(8)
O(2)--C(17) 1.322(8) N(1)--C(12) 1.369(8)
N(1)--C(13) 1.315(8) N(2)--C(22) 1.378(8)
N(2)--C(23) 1.310(9)
O(1 )--Bi--O(2) 76.9(2) O(1 )--Bi--N (1) 69.9(2)
O(1)--Bi--N(2) 144.9(2) O(1)--Bi--C(1) 92.7(2)
O(2)--Bi--N(1) 146.8(2) O(2)--Bi--N(2) 68.1 (2)
O(2)--Bi--C(1) 91.8(2) N(1)--Bi--N(2) 145.0(2)
N(1)--Bi---C(1) 88.9(2) N(2)--Bi--C(1) 85.8(2)
Bi--O(1 )--C(7) 121.4(4) Bi--O(2)--C(17) 123.8(4)
Bi--N(1)--C(12) 108.9(4) Bi---N(1)--C(13) 129.4(5)
C(12)--N(1)--C(13) 120.4(6) Bi--N(2)--C(22) 108.5(4)
Bi--N(2)--C(23) 130.7(5) C(22)--N(2)--C(23) 120.3(6)
A stereochemically active lone pair of electrons, Iocalised on the bismuth centre, may be expected
to occupy a position opposite the phenyl substituent. The overall geometry found for
PhBi(MeOx)2 is similar to that in the closely related compounds bis(1-oxopyridine-2-
thiolato)phenylbismuth(lll) [24] and chlorobis(2-phenylquinolin-8-thiolato)bismuth(lll) [25]. Further,
the association between centrosymmetrically related molecules is similar to that in bis(1-
oxopyridine-2-thiolato)phenylbismuth(lll). Thus, in the lattice of PhBi(MeOx)2 centrosymmetrically
related molecules approach each other so as to bring the two planar portions of the molecules into
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close proximity. The average separation between the two Bi(MeOx)2 moieties is 3.20 , which is
smaller than the sum of two phenyl ring van der Waals radii [26], suggesting significant -
interactions between them.
The bismuth-carbon distance is comparable with that of the related bis(1-ooxopyridine-2-
thiolato)phenylbismuth(lll) and the average bond distance [27] of Ph3Bi (2.26 A). Perhaps
surprisingly the Bi-O distances are comparable with those of Ph3Bi(Ox or MeOx)CI (2.175(7) [23]
and 2.19(2) [21], hence the effects of both a lower oxidation state and lower coordination number
in PhBi(MeOx)2 appear to cancel each other. However <Bi-N> is significantly shorter than Bi-N of
Ph3Bi(Ox or MeOX)CI (2.807(10) [23] and 2.71(2) [21]) suggesting a stronger interaction in the
bismuth(Ill) compound. Nevertheless <Bi-N> is rather larger than Bi-N (2.533(6))in 2-(2’-
pyridyl)phenylbismuth(lll) bis(N,N-diethyldithiocarbamate) [28] despite the lower coordination
number in the present compound. Possibly the steric effect of the methyl groups causes some
lengthening.
Growth Inhibition and Antitumour Testing
In vitro examination
The results of testing several (quinolin-8-olato)bismuth(lll) compounds against L1210 mouse
leukaemia cells, the corresponding cisplatin resistant line L1210/DDP, and the human ovarian
carcinoma (SKOV-3) are summarised in Table 3.
TABLE 3. In vitro growth inhibition results for bismuth(Ill) compounds against L1210,
L1210/DDP and SKOV-3
Compounda IC50/#Mb
L1 21 0 L1210/DDP SKOV-3
H(Ox) 4.1 0.77 6.8
H(MeOx) 8.3 3 85
Bi(Ox)3 0.26 0.33 0.29
Bi(Ox)21 0.25 0.22 0.77
PhBi(Ox)2.EtOH 0.1 9 0.28 0.75
PhBi(MeOx)2 0.56 0.37 2.9
[NaPhBi(Ox)3] 0.34 0.12 0.64
[KPhBi(Ox)3] 0.35 0.27 0.66
Bi(OH)3 > 5 > 5 n.d.
Ph3Bi 42 n.d. n.d.
Ph2Bil 0.29 0.31 n.d.
PhBil2 1.3 1.1 n.d.
cisplatin 0.6 6.7 3.1
a Compounds administered as solutions in < 1% Me2SO in media.
b IC50 minimum concentration (M) required to inhibit the growth of cancer cells by 50%.
n.d no data
Most of the compounds showed excellent activity when compared with the clinically used cisplatin.
H(Ox) shows very good activity against L1210/DDP but H(MeOx)is much less effective especially
against L1210/DDP and SKOV-3, perhaps owing to steric repulsion by the 2-methyl substituent.
Coordination to bismuth enhances the activity of the free H(Ox) and H(MeOx) ligands. Similarly, the
microbial or fungicidal activity of H(Ox)is enhanced by co-administrations of metals [29].
Enhancement of the in vivo anticancer activity of 6-mercaptopurine by bismuth(Ill) is known [4]. The
possibility that bismuth is enhancing delivery of active H(Ox) or H(MeOx), as proposed for 6-
mercaptopurine [4], can be ruled out in view of the very poor activity of H(MeOx) towards DDP and
SKOV-3 when compared with the high activities of PhBi(MeOx)2. This is reinforced by the.high
activity observed for Ph2Bil and PhBil2. The dependence of activity on the ligands varies as
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Bi(OH)3 Ph3Bi < PhBil2 < PhBi(MeOx)2 < Ph2Bil PhBi(Ox)2
Thus, the activity of monophenylbismuth(lll) compounds, PhBiX2, is greater for X Ox or MeOx
than for X=I. It is possible that a partially hydrolysed ’in situ-delivered’ mono- or diaryl-bismuth(lll)
compound is the active species, reinforced in the case of PhBi(Ox or MeOx)2 by the activity of H(Ox
or MeOx). Interestingly the bimetallic complexes [1] [MPhBi(Ox)3] (M Na or K) have comparable
activities to PhBi(Ox)2, suggesting that their activity may involve similar species. Perhaps
triphenylbismuth is inactive because it is inert to hydrolysis.
In vivo activity
The results of testing PhBi(Ox)2.EtOH and [KPhBi(Ox)3] against the solid mouse
plasmacytoma, ADJ/PC6 are given in Table 4.
TABI..I 4. In vivo testing results for bismuth(Ill) compounds, administered as a suspension in
peanut oil, against PC6 in mice
Compound Dose %T/Ca
PhBi(Ox)2.EtOH 30 mg/kg i.p. 89
[KPhBi(Ox)3] 30 mg/kg i.p. 146
cisplatin 6 mg/kg i.p. 0.5
a %T/C mean tumour weight of drug treated animal/mean tumour weight of controls, where values
less than 75% are considered to indicate activity
Disappointingly, the compounds are inactive. This may be attributable to delivery problems as the
complexes were completely insoluble in the delivery medium. The bimetallic [KPhBi(Ox)3] was also
tested against P388 leukaemia (Table 5), with the compound delivered intraperitoneally as a
solution in Me2SO. Three separate concentrations were examined including the maximum
tolerated dose but no activity was detected. These results contrast the reported in vivo activity of 6-
mercaptopurinebismuth(lll) complexes [4], the methylbismuth(lll) thiolates [7], and, more closely
relevant, Ph2BiO2CR (R Et, iPr or Ph) [6], for which activity against P388 leukaemia (T/C 147-
168% for doses of 50-200 mg/kg) was recorded [6]. Of relevance to the latter observation is that
diphenylbismuth(lll) carboxylates have been shown to be highly sensitive to hydrolytic cleavage of
aryl groups [30]. For PhBi(Ox or MeOx)2, the contrast between the excellent activity in vitro and the
lack of activity in vivo is dramatic, and points to delivery problems in animal models. This has not
been overcome by dissolution of the low solubility drugs in Me2SO, where precipitation on injection
into aqueous biological fluids may deactivate the compounds.
TABLE 5. In vivo testing results for [KPhBi(Ox)3], dissolved in dimethyl sulfoxide, against P388
leukaemia in mice
Dose %T/Ca
20 mg/kg i.p. 05
10 mg/kg i.p. 11
2 mg/kg i.p. 08
5-Fluorouracilb 200
a %T/C was calculated as the ratio of survival time of treated animals over control animals, where
compounds with %T/C greater that 125% are considered to have some activity
b positive control
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